Abstract: Integrin ligands having serum stability and affinity for ?v?6 integrins are described. Compositions comprising ?v?6 integrin ligands having serum stability and having affinity for ?v?6 integrins and methods of using them are also described.

Abstract: A portable blower fan assembly that includes a housing that forms a pair of air tunnels. The pair of air tunnels are configured to provide a first airflow path across a surface in a downward direction. The portable blower fan assembly further includes a pair of fan assemblies. Each fan assembly is positioned within one of the air tunnels with a downward angle. The portable blower fan assembly further includes a power supply that is configured to provide electrical power to the first motor and the second motor.

Abstract: A wire grid polarizer having a mirror layer is laminated with a colored film. The colored film provides a scratch protection of the mirror layer of the wire grid polarizer and provides a colored mirror appearance of an optical lens made with such wire grid polarizer. The colored film laminated wire grid polarizer shows different intensities between the transmitted and reflected colors when the wire grid polarizer is paired with a particular colored film. The wire grid polarizer is deposited on a structured surface of a photochromic film to form a photochromic wire grid polarizer.

Abstract: The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents or siRNAs, able to inhibit Complement Component C3 (C3) gene expression. Also disclosed are pharmaceutical compositions that include C3 RNAi agents and methods of use thereof. The C3 RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosanine, to facilitate the delivery to hepatocyte cells. Delivery of the C3 RNAi agents in vivo provides for inhibition of C3 gene expression. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms mediated in part by C3 gene expression, including IgA nephropathy, C3 glomerulopathy, paroxysmal nocturnal hemoglobinuria, and/or other complement-mediated renal diseases.

Abstract: The present invention relates generally to the inspection of pipes, and the like, and more particularly to the remote inspection of ferromagnetic pipes. The invention teaches apparatus comprising, in combination: a vehicle equipped with a plurality of wheels capable of propelling the vehicle within a predetermined ferromagnetic environment to be inspected; means for remotely applying drive forces to said wheels; said wheels including a plurality of passive non-driven rollers; said passive rollers including magnetized means; means for acquiring visual images of the condition of said pipes; and means for remotely accessing said visual images; thereby enabling remote inspection of said pipes. An immediate environment in which the use of the present invention is contemplated is in inspection of ferromagnetic pipes which are located above and/or below ground.

Abstract: Described are improved linking agents that are useful for facilitating the attachment of targeting groups, pharmacokinetic (PK) enhancers or modifiers, or other delivery agents to oligonucleotides. The described linking agents may exhibit improved reaction yields, stability, and biological activity, particularly when used in connection with oligonucleotide-based compounds, such as RNA interference (RNAi) agents.

Abstract: The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents or siRNAs, able to inhibit Complement Component C3 (C3) gene expression. Also disclosed are pharmaceutical compositions that include C3 RNAi agents and methods of use thereof The C3 RNAi agents disclosed herein may be conjugated to targeting ligands, including ligands that comprise N-acetyl-galactosamine, to facilitate the delivery to hepatocyte cells. Delivery of the C3 RNAi agents in vivo provides for inhibition of C3 gene expression. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms mediated in part by C3 gene expression, including IgA nephropathy, C3 glomerulopathy, paroxysmal nocturnal hemoglobinuria, and/or other complement-mediated renal diseases.

Abstract: The subject matter of this specification can be embodied in, among other things, a method of igniting an air/fuel mixture in an internal combustion engine includes receiving an air/fuel mixture into a pre-combustion chamber, the pre-combustion chamber enclosing a portion of an igniter, igniting the air/fuel mixture in in the pre-combustion chamber with the igniter to produce a flame, directing the flame to eject the pre-combustion chamber through a collection of passages in a wall of the pre-combustion chamber, toward a peripheral wall of a main combustion chamber of the internal combustion engine, igniting, by the flame, air/fuel mixture in the main combustion chamber adjacent the peripheral wall, and then igniting air/fuel mixture in the main combustion chamber in a central region of the main combustion chamber with a propagating flame front of the ignited air/fuel mixture or a portion of the directed flame adjacent the peripheral wall.

Abstract: Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a Superoxide Dismutase 1 (SOD1) gene. The SOD1 RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an SOD1 gene. Pharmaceutical compositions that include one or more SOD1 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described SOD1 RNAi agents to central nervous system (CNS) tissue, in vivo, provides for inhibition of SOD1 gene expression and a reduction in SOD1 activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including amyotrophic lateral sclerosis (ALS.).

Abstract: Methods, systems, and apparatus, including computer programs encoded on a computer storage medium that generates lane path descriptors for use by autonomous vehicles. One of the methods includes receiving data that defines valid lane paths in a scene in an environment. Each valid lane path represents a path through the scene that can be traversed by a vehicle. User interface presentation data can be provided to a user device. The user interface can contain: (i) a first display area that displays a first visual representation of the sensor measurement; and (ii) a second display area that displays a second visual representation of the set of valid lane paths. User input modifying the second visual representation of the set of valid lane paths can be received; and in response to receiving the user input, the set of valid lane paths of the scene in the environment can be modified.

Abstract: Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a Superoxide Dismutase 1 (SOD1) gene. The SOD1 RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an SOD1 gene. Pharmaceutical compositions that include one or more SOD1 RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described SOD1 RNAi agents to central nervous system (CNS) tissue, in vivo, provides for inhibition of SOD1 gene expression and a reduction in SOD1 activity, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including amyotrophic lateral sclerosis (ALS.

Abstract: Methods, systems, and apparatus, including computer programs encoded on a computer storage medium that generates lane path descriptors for use by autonomous vehicles. One of the methods includes receiving data that defines valid lane paths in a scene in an environment. Each valid lane path represents a path through the scene that can be traversed by a vehicle. User interface presentation data can be provided to a user device. The user interface can contain: (i) a first display area that displays a first visual representation of the sensor measurement; and (ii) a second display area that displays a second visual representation of the set of valid lane paths. User input modifying the second visual representation of the set of valid lane paths can be received; and in response to receiving the user input, the set of valid lane paths of the scene in the environment can be modified.

Abstract: Described are improved linking agents that are useful for facilitating the attachment of targeting groups, pharmacokinetic (PK) enhancers or modifiers, or other delivery agents to oligonucleotides. The described linking agents may exhibit improved reaction yields, stability, and biological activity, particularly when used in connection with oligonucleotide-based compounds, such as RNA interference (RNAi) agents.

Abstract: The subject matter of this specification can be embodied in, among other things, a method of igniting an air/fuel mixture in an internal combustion engine includes receiving an air/fuel mixture into a pre-combustion chamber, the pre-combustion chamber enclosing a portion of an igniter, igniting the air/fuel mixture in in the pre-combustion chamber with the igniter to produce a flame, directing the flame to eject the pre-combustion chamber through a collection of passages in a wall of the pre-combustion chamber, toward a peripheral wall of a main combustion chamber of the internal combustion engine, igniting, by the flame, air/fuel mixture in the main o combustion chamber adjacent the peripheral wall, and then igniting air/fuel mixture in the main combustion chamber in a central region of the main combustion chamber with a propagating flame front of the ignited air/fuel mixture or a portion of the directed flame adjacent the peripheral wall.

Abstract: Methods, computer systems, and apparatus, including computer programs encoded on computer storage media, for generating and editing object track labels for objects detected in video data. One of the methods includes obtaining a video segment comprising multiple image frames associated with multiple time points; obtaining object track data specifying a set of object tracks; providing, for presentation to a user, a user interface for modifying the object track data, the user interface displaying object timeline representations of the object tracks; receiving one or more user inputs that indicate one or more modifications to the object timeline representations; updating the object timeline representations displayed in the timeline display area; and updating the object track data according to the updated object timeline representations.

Abstract: The subject matter of this specification can be embodied in, among other things, a method of igniting an air/fuel mixture in an internal combustion engine includes receiving an air/fuel mixture into a pre-combustion chamber, the pre-combustion chamber enclosing a portion of an igniter, igniting the air/fuel mixture in in the pre-combustion chamber with the igniter to produce a flame, directing the flame to eject the pre-combustion chamber through a collection of passages in a wall of the pre-combustion chamber, toward a peripheral wall of a main combustion chamber of the internal combustion engine, igniting, by the flame, air/fuel mixture in the main combustion chamber adjacent the peripheral wall, and then igniting air/fuel mixture in the main combustion chamber in a central region of the main combustion chamber with a propagating flame front of the ignited air/fuel mixture or a portion of the directed flame adjacent the peripheral wall.

Abstract: The present disclosure relates to RNAi agents, for example, double stranded RNAi agents, able to inhibit HIF-2 alpha (EPAS1) gene expression. Also disclosed are pharmaceutical compositions that include HIF-2 alpha RNAi agents and methods of use thereof. The HIF-2 alpha RNAi agents disclosed herein may be linked or conjugated to targeting ligands (such as compounds that have affinity for integrins, including alpha-v-beta-3 and alpha-v-beta-5 integrins) and pharmacokinetic (PK) enhancers, to facilitate the delivery to cells and tissues, including to clear cell renal cell carcinoma (ccRCC) cells and tumors. Delivery of compositions comprising the HIF-2 alpha RNAi agents in vivo provides for inhibition of HIF-2 alpha gene expression. The HIF-2 alpha RNAi agents can be used in methods of treatment of various diseases and disorders, including ccRCC.

Abstract: Integrin ligands having serum stability and affinity for ?v?6 integrins are described. Compositions comprising ?v?6 integrin ligands having serum stability and having affinity for ?v?6 integrins and methods of using them are also described.

Abstract: Integrin ligands having serum stability and affinity for ?v?6 integrins are described. Compositions comprising ?v?6 integrin ligands having serum stability and having affinity for ?v?6 integrins and methods of using them are also described.

Abstract: A method of controlling combustion in an internal combustion engine includes measuring parameters of combustion in a cylinder of the engine during a combustion phase of the cylinder, after igniting an air/fuel charge in the cylinder, and calculating the heat release of combustion in the cylinder based on the measured parameters. An auto-ignition event of the air/fuel charge is identified based on the calculated heat release, and, based at least in part on the identified auto-ignition event, at least one of ignition timing in the cylinder for the next combustion phase of the cylinder or an amount of exhaust gas supplied to the cylinder for the next combustion phase of the cylinder is controlled to cause an auto-ignition event of the air/fuel charge in the next combustion phase to shift toward a specified crank angle.